Antibiotic developer company Achaogen has filled for bankruptcy earlier this year as sales of its drugs failed to keep pace with operational costs as antibiotics are short-term drugs with limited shelf lives. The economic fundamentals may leave the world with very few antibiotics as the bugs are currently retooling much faster than human medical science. It is probably time to change the way we play organise funding and rewards. Thanks to Len Elikhis for highlighting this article. Click here to read more.